Clinical Trials at University of Minnesota
As of July 2026, 293 paid clinical trials are recruiting at University of Minnesota, located at University of Minnesota Clinical Research Unit (CRU), 516 Delaware St SE, Minneapolis, MN 55455 in Minneapolis, Minnesota. Active studies at this site cover conditions such as Heart Failure, Acute Myeloid Leukemia and Ovarian Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
293 clinical trials at University of Minnesota
·Clear filters·↓ Download CSVA Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
US National OCS Heart Perfusion (OHP) Registry
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
Prophylactic Reinforcement of Ventral Abdominal Incisions Trial
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
CAR-T Long Term Follow Up (LTFU) Study
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Diagnosing Epilepsy To EffeCT Change
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
About research studies in Minneapolis
Minneapolis has approximately 968 recruiting research studies across a wide range of therapeutic areas. Minnesota is anchored by Mayo Clinic in Rochester and University of Minnesota Medical Center — nationally ranked for cancer, cardiology, and rare-disease research.
Common conditions studied in Minneapolis
- Heart Failure (18 active studies). Heart failure trials explore SGLT-2 inhibitors, novel myosin modulators, and device-based therapies for both reduced and preserved ejection fraction.
- Acute Myeloid Leukemia (16 active studies). Leukemia trials evaluate targeted inhibitors, CAR-T cell therapies, and novel combinations for acute and chronic forms of the disease.
- Ovarian Cancer (13 active studies). Ovarian cancer research examines PARP inhibitors, maintenance therapies, and antibody-drug conjugates for recurrent and platinum-resistant disease.
- Breast Cancer (12 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Endometrial Cancer (12 active studies). Recruiting Endometrial Cancer studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Parkinson Disease (12 active studies). Parkinson's disease studies evaluate disease-modifying therapies, gene therapies, and advanced symptomatic treatments for motor and non-motor symptoms.
Leading research sponsors in Minneapolis
- University of Minnesota
- National Cancer Institute (NCI)
- Masonic Cancer Center, University of Minnesota
- VA Office of Research and Development
- Children's Oncology Group
Local regulations and guidelines
Clinical trials in Minnesota are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Minnesota research additionally follows state public health department oversight and any applicable state privacy statutes.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Minneapolis. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Minneapolis
Hipa.ai aggregates every recruiting study in Minneapolis from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Minneapolis?
There are approximately 968 recruiting clinical trials in Minneapolis, Minnesota listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Minneapolis pay participants?
Most recruiting trials in Minneapolis compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Minneapolis?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Minneapolis?
The most common conditions under active study in Minneapolis include Heart Failure (18), Acute Myeloid Leukemia (16), Ovarian Cancer (13), Breast Cancer (12), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Minneapolis?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Minneapolis on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Minneapolis?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Minneapolis?
Recruiting research sites in Minneapolis include University of Minnesota, Abbott-Northwestern Hospital, Hennepin County Medical Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Minneapolis right now?
The largest active categories in Minneapolis are Cancer & tumors (269), Cardiovascular (75), Neurology & pain (56). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of University of Minnesota?
University of Minnesota is located at University of Minnesota Clinical Research Unit (CRU), 516 Delaware St SE, Minneapolis, MN 55455. Use the Google Maps link in the intro above to get directions.